Indications And Dose
HIV infection ▶BY MOUTH ▶Adult: 1 tablet once daily
PDF page 708
Loading InternPractice…
Drug reference
HIV infection ▶BY MOUTH ▶Adult: 1 tablet once daily
PDF page 708
Dispense in original container (contains desiccant).
PDF page 709
MHRA/CHM ADVICE: ELVITEGRAVIR BOOSTED WITH COBICISTAT: AVOID USE IN PREGNANCY DUE TO RISK OF TREATMENT FAILURE AND MATERNAL-TO-CHILD TRANSMISSION OF HIV-1 (APRIL 2019) Pharmacokinetic data show mean exposure of elvitegravir boosted with cobicistat (available in combination in Genvoya ® and Stribild ®) to be lower during the second and third trimesters of pregnancy than postpartum. Low elvitegravir exposure may be associated with an increased risk of treatment failure and an increased risk of HIV-1 transmission to the unborn child. For further information, see Pregnancy.
PDF page 708
→Appendix 1: cobicistat. elvitegravir. tenofovir disoproxil
PDF page 708
▶Common or very common Appetite decreased. asthenia. constipation. diarrhoea. dizziness. electrolyte imbalance. flatulence. gastrointestinal discomfort. headache. hyperbilirubinaemia. hyperglycaemia. hypersensitivity. hypertriglyceridaemia. nausea. neutropenia. pain. rash pustular. skin reactions. sleep disorders. vomiting ▶Uncommon Anaemia. angioedema. depression (in patients with history of depression or psychiatric illness). muscle weakness. myopathy. pancreatitis. proteinuria. renal failure. renal tubular disorders. suicidal ideation (in patients with history of depression or psychiatric illness) ▶Rare or very rare Acute tubular necrosis. hepatic disorders . lactic acidosis. nephritis. nephrogenic diabetes insipidus . osteomalacia ▶Frequency not known Autoimmune disorder. Grave’s disease. inflammation. osteonecrosis. weight increased
PDF pages 708, 709
Women of child- bearing potential should use effective contraception during treatment (if using a hormonal contraceptive, it must contain norgestimate as the progestogen and at least 30 micrograms ethinylestradiol).
PDF page 709
Manufacturer advises not to be initiated during pregnancy due to low elvitegravir exposure; women who become pregnant during therapy should be switched to an alternative regimen.
PDF page 709
Manufacturer advises caution (increased risk of hepatic side-effects); avoid in severe impairment (no information available).
PDF page 709
If eGFR less than 90 mL/minute/1.73 m2, only initiate Stribild ® if other treatments cannot be used (avoid initiating Stribild ® if eGFR less than 70 mL/minute/1.73 m2); if eGFR less than 70 mL/minute/1.73 m2, only continue Stribild ® if potential benefit outweighs risk (discontinue Stribild ® if eGFR less than 50 mL/minute/1.73 m2).
PDF page 709
Test urine glucose before treatment, then every 4 weeks for 1 year and then every 3 months.
PDF page 709
There can be variation in the licensing of different medicines containing the same drug. Tablet CAUTIONARY AND ADVISORY LABELS 21 ▶Stribild (Gilead Sciences International Ltd) Cobicistat 150 mg, Elvitegravir 150 mg, Emtricitabine 200 mg, Tenofovir disoproxil (as Tenofovir disoproxil fumarate) 245 mg Stribild 150mg/150mg/200mg/245mg tablets | 30 tablet P £879.51 eiiii F 683
PDF page 709
Patients or carers should be given advice on how to administer Stribild ®. Missed doses If a dose is more than 18 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.
PDF page 709
1 tablet once daily
First-line fragment. Read the complete Indications and Dose section above.
PDF page 708